Novel SOCS1-Based Peptides Show Promise for Liver Disease and Metabolic Dysfunction

The global prevalence of obesity and type 2 diabetes continues to rise, leading to a surge in associated complications, particularly non-alcoholic fatty liver disease (NAFLD) and its more severe form, non-alcoholic steatohepatitis (NASH). These conditions are characterized by chronic inflammation, insulin resistance, and progressive liver damage, for which effective therapeutic options remain limited. This study addresses the critical need for new therapeutic strategies that can simultaneously target both metabolic dysfunction and liver pathology.

Treatment with SOCS1-TP1 significantly improved several metabolic and hepatic outcomes in both models. In DIO mice, SOCS1-TP1 reduced body weight gain by 15% (p<0.05) and improved glucose tolerance by 32% (p<0.01) compared to controls. Liver steatosis (fat accumulation) was dramatically reduced, showing a 48% decrease in lipid droplet area (p<0.001). The most striking finding was a 65% reduction in liver inflammation and a 2.7-fold decrease in fibrosis markers (e.g., α-SMA expression) in the SOCS1-TP1-treated db/db mice, indicating significant protection against advanced liver disease. Furthermore, circulating levels of pro-inflammatory cytokines like TNF-α and IL-6 were lowered by 30-40% (p<0.05), alongside a 25% improvement in insulin sensitivity.